care Companies, Inc. (“iRemedy” or “the Company”), pioneer of the iRemedy™ medical supply marketplace, today announced that in association with the Company’s effort to procure and deliver one billion FDA-approved hypodermic needles and syringes in support of COVID-19 vaccination programs worldwide, over 130 million units have been delivered to customers since announcing its program in November 2020. Having titled this initiative “Project Vaccinate,” iRemedy delivered over 30 million units in late 2020 and nearly 100 million units in the first six weeks of 2021 in association w...